Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;11(12):3007-3009.
doi: 10.1007/s13300-020-00943-6. Epub 2020 Oct 14.

A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

Antonio C Bossi  1 , Franco Forloni  2 , Paolo L Colombelli  3
Affiliations

A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

Antonio C Bossi et al. Diabetes Ther. 2020 Dec.
No abstract available

Keywords: Pleiotropic effects of SGLT2-i; SGLT2-i in COVID-19; Sodium–glucose cotransporter 2 inhibitors (SGLT2-i).

PubMed Disclaimer

References

    1. Patoulias D, Papadopoulos C, Katsimardou A, Toumpourleka M, Doumas M. Sodium–glucose cotransporter 2 inhibitors and major COVID-19 outcomes: promising mechanisms, conflicting data, and intriguing clinical decisions. Adv Ther. 2020. 10.1007/s13300-020-00942-7. - PMC - PubMed
    1. Verma S. Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits. Am J Cardiol. 2019;15(124):S36–44. doi: 10.1016/j.amjcard.2019.10.028. - DOI - PubMed
    1. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019;45(3):213–223. doi: 10.1016/j.diabet.2019.01.008. - DOI - PubMed
    1. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial) Diabetes Care. 2018;41(8):1801–1808. doi: 10.2337/dc18-0165. - DOI - PubMed
    1. Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291–1298. doi: 10.1111/dom.13670. - DOI - PubMed

LinkOut - more resources